Background: Histone 3.3 (H3.3) hotspot mutations in bone tumors occur in the vast majority of giant cell tumors of bone (GCTBs; 96%), chondroblastomas (95%) and in a few cases of osteosarcomas. However, clinical presentation, histopathological features, and additional molecular characteristics of H3.3 mutant osteosarcomas are largely unknown. Methods: In this multicentre, retrospective study, a total of 106 conventional high-grade osteosarcomas, across all age groups were re-examined for hotspot mutations in the H3.3 coding genes H3F3A and H3F3B. H3.3 mutant osteosarcomas were re-evaluated in a multidisciplinary manner and analyzed for genome-wide DNA-methylation patterns and DNA copy number aberrations alongside H3.3 wild-type osteosarco...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Osteosarcoma is the most common pediatric primary non-hematopoietic bone tumor. Survival of these yo...
BACKGROUND: Histone 3.3 (H3.3) hotspot mutations in bone tumors occur in the vast majority of giant ...
Background: Histone 3.3 (H3.3) hotspot mutations in bone tumors occur in the vast majority of giant ...
Contains fulltext : 173988.pdf (publisher's version ) (Open Access)BACKGROUND: His...
It is recognized that some mutated cancer genes contribute to the development of many cancer types, ...
The neoplastic stromal cells of giant cell tumor of bone (GCTB) carry a mutation in H3F3A, leading t...
Driver mutations in the two histone 3.3 (H3.3) genes, H3F3A and H3F3B, were recently identified by w...
It is recognized that some mutated cancer genes contribute to the development of many cancer types, ...
Osteosarcoma is a primary malignancy of bone that affects children and adults. Here, we present the ...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Mutually exclusive histone 3.3 gene mutations have been recognized in chondroblastoma and giant cell...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Osteosarcoma is the most common pediatric primary non-hematopoietic bone tumor. Survival of these yo...
BACKGROUND: Histone 3.3 (H3.3) hotspot mutations in bone tumors occur in the vast majority of giant ...
Background: Histone 3.3 (H3.3) hotspot mutations in bone tumors occur in the vast majority of giant ...
Contains fulltext : 173988.pdf (publisher's version ) (Open Access)BACKGROUND: His...
It is recognized that some mutated cancer genes contribute to the development of many cancer types, ...
The neoplastic stromal cells of giant cell tumor of bone (GCTB) carry a mutation in H3F3A, leading t...
Driver mutations in the two histone 3.3 (H3.3) genes, H3F3A and H3F3B, were recently identified by w...
It is recognized that some mutated cancer genes contribute to the development of many cancer types, ...
Osteosarcoma is a primary malignancy of bone that affects children and adults. Here, we present the ...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Mutually exclusive histone 3.3 gene mutations have been recognized in chondroblastoma and giant cell...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Osteosarcoma is the most common pediatric primary non-hematopoietic bone tumor. Survival of these yo...